A pilot study to determine the impact on dyslipidemia of the addition of tenofovir to stable background antiretroviral therapy in HIV-infected subjects
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2010 Planned end date (1 Jul 2007) added as reported by ClinicalTrials.gov record.
- 07 Jun 2010 Actual initiation date (May 2005) added as reported by ClinicalTrials.gov.
- 21 May 2010 Results have been published in AIDS.